Editas Medicine, Inc.: financial statements
Price
$2.17
November 13, 2026Market cap $335M
What Ploutos Investor adds for Editas Medicine
Part of Ploutos Investor, €9.99 a month
- The full history: 10 fiscal years, from 2016
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has fallen 21% since Nov 9, 2026, when the 10-Q these figures come from was filed ($2.75 then, $2.17 on Nov 13, 2026). The figures date from before that move.10-Q
Financial statements
Each fiscal year's income statement, balance sheet and cash flow as the company filed them, and the latest quarters.
Click a line to see it on the chart.
Revenue
-28.0% a year over 2 years
Financial statements
EDIT's revenue, profits and cash flows from 2016 to 2022, 7 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
Amounts are in dollars as the company filed them in its annual reports (10-K or 20-F). Those reporting in another currency are converted at each fiscal year-end rate. Shares and earnings per share are adjusted for splits.
Debt and obligations
What the company owes beyond the loans on its balance sheet, and when it pays, from the notes to its annual report: debt maturities, leases, pension plans, goodwill by segment, and how it gets to the tax it pays.
Leases
Dec 31, 2025Operating leases
$18M
Finance leases
–
The liability is the present value of the rent still to pay, at December 31, 2025. It is not counted in the ladder's debt. The filing
From the statutory to the effective tax rate, 2025
Dec 31, 2025Statutory rate
21.0%
Effective rate
0.0%
The company paid 0.0% in tax on its profit, 21.0 points below the US federal rate (21.0%). Below, the reasons it gives.
Statutory rate
21.0%
Change in valuation allowance
-20.3 pts
Difference the filing does not itemize
-0.7 pts
Effective rate
0.0%
One point is 1% of profit before tax. The lines are as the company states them in the notes to its annual report. The filing
Earnings quality
How the reported earnings were made, read from the filings. A description, not a score: our tests found no link between these measures and later share returns.
Receivables and inventory against sales
In the quarter to Sep 30, 2026, sales were +37.4% on the same quarter a year earlier, and receivables -5.0%.
- a year earlier 98 days
- 68 days
Balances at Sep 30, 2026 and Sep 30, 2025, against the sales and cost of sales of the quarter ending on each date; a fourth quarter is the fiscal year less its first nine months. Same quarter against same quarter, so the season is the same.
The earnings per share split is not shown: a figure it needs is missing from the company's structured filings.
The allowance for doubtful accounts is not shown: the company does not tag it in its structured filings.
The tax part is not shown: a figure it needs is missing from the company's structured filings.
A reading is called out when it is above the 90th percentile of the same reading across the S&P 500, or, for a fall, below the 10th, as measured on 9 November 2026. Each part uses only the company's own filings.
The full analysis
What do Editas Medicine's filings show?
These are Editas Medicine's figures from its filings. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
How much revenue did EDIT have in 2025?
Editas Medicine had revenue of $41M and net income of -$160M in fiscal 2025, a net margin of -395.0%.
How much debt does EDIT have?
On December 31, 2025 Editas Medicine had total assets of $187M, debt of $59M and shareholders' equity of $27M.
How much free cash flow does EDIT have?
In fiscal 2025 Editas Medicine had cash from operations of -$165M and spent $607.0K on capital expenditure, leaving -$166M of free cash flow.
Where are the figures from?
From Editas Medicine, Inc.'s annual and quarterly reports to the SEC, read from the structured data (XBRL) it files itself.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.